Punctal plug deemed beneficial in ocular surface disease

May 4, 2018

(HealthDay)—For patients with ocular surface disease (OSD) using prostaglandin analogue monotherapy, a punctal plug improves OSD and reduces intraocular pressure (IOP), according to a study published online April 26 in Clinical & Experimental Ophthalmology.

Justin C. Sherwin, M.B., B.S., from the University of Oxford in the United Kingdom, and colleagues conducted a randomized controlled trial to examine whether a punctal improves OSD and reduces IOP in patients using prostaglandin analogue monotherapy. Out of 60 eligible subjects with symptomatic OSD from glaucoma clinics, 48 participated. One eye received an inferior punctal plug, so the fellow eye was considered a control. At baseline and after six weeks, ocular surface index, tear-film breakup time, Oxford Cornea Score, tear osmolarity, and IOP were compared.

The researchers found that following plug insertion there was a reduction in OSD index (mean difference [MD], 14.5). In eyes receiving plugs, the tear-film breakup time increased compared with control eyes (MD, 2.3 seconds), while there was a decrease in the Oxford Cornea Score (MD, 0.5) and tear osmolarity (MD, 10 mOsm/L). IOP was lowered significantly with punctal plugs (MD, 1.5 mm Hg). Efficacy was similar regardless of prostaglandin preservative status or lubricant drop use in subgroup analyses. Extrusion occurred in 8.5 percent, and epiphora increased in 6.5 percent of eyes, although plugs were well tolerated.

"Punctal plug insertion improves subjective and objective measures of OSD and results in a reduced IOP in patients with symptomatic ocular surface disease using analogue monotherapy," the authors write.

Explore further: Omega-3 essential fatty acids may protect corneal nerves in dry eye

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Omega-3 essential fatty acids may protect corneal nerves in dry eye

March 21, 2017
(HealthDay)—Oral, long-chain omega-3 (ω-3) essential fatty acid (EFA) supplementation is neuroprotective to corneal nerves for patients with dry eye disease, according to a study published online March 12 in Ophthalmic ...

Tear duct implant effective at reducing pain and inflammation in cataract surgery patients

October 19, 2014
The first tear duct implant developed to treat inflammation and pain following cataract surgery has been shown to be a reliable alternative to medicated eye drops, which are the current standard of care, according to a study ...

Open-angle glaucoma: Poor data for the fixed combination tafluprost/timolol

April 7, 2015
The fixed combination of the drugs tafluprost and timolol (trade name: Taptiqom) has been approved in Germany since December 2014 for adults with open-angle glaucoma or increased intraocular pressure (ocular hypertension). ...

Prostaglandin analogs impact circadian IOP-related patterns

December 9, 2015
(HealthDay)—For patients with glaucoma, prostaglandin analogs seem to affect circadian intraocular pressure (IOP)-related patterns, according to a study published in the December issue of Clinical & Experimental Ophthalmology.

Combo Tx superior for polypoidal choroidal vasculopathy

October 9, 2017
(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal vasculopathy (PCV), according ...

Low vitamin D tied to dry eye syndromes

August 23, 2015
(HealthDay)—Patients with vitamin D deficiency should be evaluated for dry eye syndromes, according to a study published online Aug. 13 in the International Journal of Rheumatic Diseases.

Recommended for you

Widespread errors in 'proofreading' cause inherited blindness

October 12, 2018
Mistakes in "proofreading" the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) caused by mutations in splicing factors.

Gene therapy breakthrough in treating rare form of blindness

October 9, 2018
Positive results of the world's first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in Nature Medicine.

Gene changes driving myopia reveal new focus for drug development

October 9, 2018
Myopia (nearsightedness) and hyperopia (farsightedness) develop through different molecular pathways, according to a new study publishing October 9 in the open-access journal PLOS Biology by Andrei Tkatchenko of Columbia ...

Dynamin-binding protein linked to congenital cataracts

October 4, 2018
Cataracts, a condition in which the eyes' natural lenses get clouded, are the most common cause of vision loss in older people and can be corrected by routine surgery. But congenital cataracts, which occur in infants and ...

Eye discovery to pave way for more successful corneal transplants

October 1, 2018
A team of eye specialists at The University of Nottingham has made another novel discovery that could help to improve the success of corneal transplants for patients whose sight has been affected by disease.

New study confirms Mediterranean diet prevents a leading cause of blindness

October 1, 2018
Evidence is mounting that a poor diet plays an important role in the development of age-related macular degeneration (AMD), a leading cause of blindness in the United States. A large collaboration of researchers from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.